Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics updates corporate presentation with pipeline data slides

Neutral Impact 1 of 5 other Written later

On October 1, 2026, Perspective Therapeutics updated its corporate presentation and filed it as Exhibit 99.1 to this Form 8-K. The filing contains no new financial results, guidance, or transaction terms, so it is an informational update rather than a change in the company's financial position.

Key points

  • Corporate presentation updated on October 1, 2026 and filed as Exhibit 99.1
  • Presentation covers three clinical-stage programs: VMT-α-NET, VMT01, and PSV359, plus CCK2R81
  • Filing states the programs have data in 2026 and references an ASCO 2026 data analysis
  • No financial figures, guidance, or transaction terms are disclosed in the 8-K text

The filing

CompanyPerspective Therapeutics, Inc. (CATX)
Form8-K, current report
Filed with the SECOct 1, 2026, 4:08 PM ET
Accession number0001193125-26-410663

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.